The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Philippe A. Cassier
Honoraria - Amgen; AstraZeneca; Merck Serono; Novartis; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Novartis; Roche
 
Salvatore Siena
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; Merck; Roche/Genentech; Seagen
 
Guzman Alonso
No Relationships to Disclose
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Ipsen; Lilly; Merck Serono; Mirati Therapeutics; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Pilar Garrido
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim (I); Bristol-Myers Squibb; Gebro Pharma (I); Janssen Biotech (I); Janssen-Cilag; Lilly; MSD Oncology; Nordic Group (I); Novartis/Pfizer; Pfizer; Roche Pharma AG; Takeda
Speakers' Bureau - AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Gilead Sciences; Janssen; Janssen (I); Janssen Oncology; MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Rovi; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
Other Relationship - Janssen Oncology; Novartis
 
Ernest Nadal
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Takeda
Research Funding - Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Jacqueline Vuky
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - Celldex (Inst); Fortis (Inst); Innocrin Pharma (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); Adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Gregory Peter Kalemkerian
Research Funding - Abbvie; Amgen; Merck; Takeda
 
Daniel W. Bowles
No Relationships to Disclose
 
Mahesh Seetharam
Stock and Other Ownership Interests - BioNTech; crispr therapeutics; Inovio Pharmaceuticals; Johnson & Johnson/Janssen; Moderna Therapeutics; Pfizer
Honoraria - Daiichi Sankyo; Horizon CME
 
Jianhua Chang
No Relationships to Disclose
 
Hui Zhang
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Chaoyang Ye
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Jennifer Green
Employment - Celldex
Stock and Other Ownership Interests - Celldex
Consulting or Advisory Role - Arvinas; Blueprint Medicines; Genocea Biosciences; Tesaro
 
Alena Zalutskaya
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; MorphoSys; Novartis; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Yun Fan
No Relationships to Disclose